DAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability ofDAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability of

Antibodies Inc. Launches Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) for Reproducible Retinal Research

DAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability of its Recombinant Guinea Pig RBPMS Antibody (Clone OTI3B7-GP, Cat. No. 1834-RBPMS)—a next-generation antibody designed to deliver superior reproducibility, specificity, and performance in retinal ganglion cell (RGC) research.

Developed under the PhosphoSolutions brand, the recombinant Guinea Pig RBPMS Antibody continues a legacy of high-performance neuroscience reagents while benefiting from Antibodies Inc.’s expanded validation, manufacturing, and global distribution infrastructure. This new recombinant mAb replaces the formerly available guinea pig polyclonal RBPMS Antibody (Cat. No. 1832-RBPMS).

RBPMS (RNA Binding Protein with Multiple Splicing) has emerged as the gold-standard marker for identifying retinal ganglion cells, supporting accurate cell identification and quantification in vision and neurodegeneration research. While guinea pig polyclonal antibodies have historically been valuable for multiplex immunofluorescence, traditional formats are limited by lot-to-lot variability and finite supply.

Our Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) addresses these limitations through recombinant engineering, eliminating lot-to-lot variability and supply constraints. The antibody combines the well-validated antigen-binding region of the OTI3B7 clone with a guinea pig IgG constant region, enabling efficient multiplexing alongside mouse and rabbit antibodies while delivering long-term consistency.

Key benefits include:

  • Recombinant RBPMS Antibody for retinal ganglion cell identification
  • Guinea Pig format for advanced multiplex immunolabeling
  • Clone OTI3B7-GP with defined amino acid sequence
  • Animal-free, serum-free production
  • Lot-to-lot reproducibility for longitudinal and multi-site studies

The antibody has been validated for immunohistochemistry (IHC) and Western blotting, providing clear and specific labeling of retinal ganglion cells in mammalian tissue samples.

The launch further reflects Antibodies Inc.’s commitment to supporting scientific discovery through a growing portfolio of specialized research brands.

Related Resources:
Explore the full PhosphoSolutions product line:
https://www.antibodiesinc.com/collections/phosphosolutions

Recombinant Guinea Pig RBPMS Antibody Product page:
https://www.antibodiesinc.com/products/anti-rbpms-antibody-recombinant-antibody-oti3b7-gp-1834-rbpms

Researchers seeking alternative host species can also access the Rabbit Polyclonal RBPMS Antibody:
https://www.antibodiesinc.com/products/anti-rbpms-antibody-1830-rbpms

Learn more about the Antibodies Inc. family of brands:
https://www.antibodiesinc.com/pages/our-brands

Available Now
The Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP, 1834-RBPMS) is available now through Antibodies Inc. and authorized global distributors.

About Antibodies Inc.
Antibodies Inc. provides researchers worldwide with rigorously validated antibodies, recombinant proteins, ELISA kits, and custom services. Through a growing portfolio of specialized brands—including PhosphoSolutions—Antibodies Inc. delivers reproducible tools that accelerate discovery across neuroscience, cell biology, and translational research.

Cision View original content:https://www.prnewswire.com/news-releases/antibodies-inc-launches-recombinant-guinea-pig-rbpms-antibody-oti3b7-gp-for-reproducible-retinal-research-302666278.html

SOURCE Antibodies Inc.

Market Opportunity
Graphite Logo
Graphite Price(GP)
$0.5617
$0.5617$0.5617
-3.91%
USD
Graphite (GP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

MAXI DOGE Holders Diversify into $GGs for Fast-Growth 2025 Crypto Presale Opportunities

MAXI DOGE Holders Diversify into $GGs for Fast-Growth 2025 Crypto Presale Opportunities

Presale crypto tokens have become some of the most active areas in Web3, offering early access to projects that blend culture, finance, and technology. Investors are constantly searching for the best crypto presale to buy right now, comparing new token presales across different niches. MAXI DOGE has gained attention for its meme-driven energy, but early [...] The post MAXI DOGE Holders Diversify into $GGs for Fast-Growth 2025 Crypto Presale Opportunities appeared first on Blockonomi.
Share
Blockonomi2025/09/18 00:00
Bank of Canada cuts rate to 2.5% as tariffs and weak hiring hit economy

Bank of Canada cuts rate to 2.5% as tariffs and weak hiring hit economy

The Bank of Canada lowered its overnight rate to 2.5% on Wednesday, responding to mounting economic damage from US tariffs and a slowdown in hiring. The quarter-point cut was the first since March and met predictions from markets and economists. Governor Tiff Macklem, speaking in Ottawa, said the decision was unanimous. “With a weaker economy […]
Share
Cryptopolitan2025/09/17 23:09
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23